Docetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC early clinical trials group
Steinar Aamdal(Humboldt-Universität zu Berlin), Jaap Verweij(Deutz (Germany)), Jacob Schachter, Ingmar Wolff(Universitätsmedizin Greifswald), Steven Kaplan(Kantonsspital Baselland), H. R. Franklin(European Organisation for Research and Treatment of Cancer), Robert Paridaens(Cornell University), J. Wanders(Eisai (United Kingdom)), Joseph Kerger(Institut Jules Bordet)
Cited by 82
Related Papers
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
|New England Journal of Medicine|2014|2.7k
Cremophor EL
|European Journal of Cancer|2001|1.6k
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
|The Lancet Oncology|2015|1.6k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k